CAM
LFCR icon

Cresset Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Cresset Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,700
Closed -$89.4K – 1631
2025
Q1 		$89.4K Hold
12,700
– – ﹤0.01% 1627
2024
Q4 		$94.4K Sell
12,700
-148
-1% -$945 ﹤0.01% 1632
2024
Q3 		$63.3K Buy
+12,848
New +$67.1K ﹤0.01% 2078

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Cresset Asset Management's LFCR Position: Q2 2025 in Review

Cresset Asset Management sold out of Lifecore Biomedical (LFCR) in Q2 2025, closing a stake of 12,700 shares — an estimated $89.4K sold.

Cresset Asset Management first reported a position in LFCR in Q3 2024 and held it in 3 quarters. The position peaked at $94.4K in Q4 2024. 86 funds tracked by Wall St. Rank hold LFCR as of Q2 2025.

  • Cresset Asset Management reported no remaining Lifecore Biomedical position as of Q2 2025 after selling out during the quarter.
  • Cresset Asset Management sold 12,700 Lifecore Biomedical shares in Q2 2025, an estimated $89.4K.
  • Cresset Asset Management first reported a position in Lifecore Biomedical in Q3 2024 and held it in 3 quarters.
  • Cresset Asset Management's Lifecore Biomedical position peaked at $94.4K in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2025.

Based on Cresset Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.